MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Novel mPGES-1 inhibitor targets pain, inflammatory diseases

University of Kentucky

It has been proposed that prostaglandin E2 (PGE2), known as the principal proinflammatory prostaglandin, is implicated in pain response and also plays a role in inflammatory diseases. Particularly, the increased PGE2 level, produced by an inducible enzyme known as microsomal PGE2 synthase-1 (mPGES-1) is an indicator of pain.

University of Kentucky researchers have identified therapeutics to inhibit this pathway in order to decrease pain and inflammation. The lead compound has been tested in various mouse and rat models of inflammation, acute and chronic pain via oral administration and parenteral administration, demonstrating that the compound was effective in all of the models tested so far, including carrageenan-induced paw edema and hyperalgesia, adjuvant-induced arthritis, formalin-induced orofacial pain, neuropathic pain, and post-operative pain. None of the other mPGES-1 inhibitors reported in literature has shown better or close anti-inflammatory and analgesic effects in these animal (mouse or rat) models. In addition, the lead compound has also been tested for its acute toxicity in mice and rats, e.g. oral administration (PO) of 3 g/kg (or 3000 mg/kg) per day for 14 days, without showing any toxicity signs in any tissues or behavior. The experiments conducted include comparison studies against Celecoxib and Oxycodone. In comparison to the novel drug, a single dose of 50 mg/kg celecoxib (PO) resulted in significant toxicity (bleeding in stomach) after 24 hours.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    503 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw